Kairos Pharma, LTD. 8-K

What Happened
Kairos Pharma, Ltd. (KAPA) announced on July 22, 2026 (8-K filed) that it entered into an Agreement for the Support of Investigator / Institution Initiated Research with Bayer HealthCare Pharmaceuticals Inc. on July 16, 2026. Under the agreement, Bayer will supply radium for Kairos’s study of radium combined with ENV-105 (carotuximab) in models of prostate cancer bone metastasis. Kairos is solely responsible for initiating, managing and financing the Study but must obtain Bayer’s prior written approval before making any material changes to study protocols.

Key Details

• Agreement date: July 16, 2026; public notice/press release issued July 22, 2026 (Exhibit 99.1).
• Sponsor roles: Bayer supplies radium; Kairos funds and runs the Study.
• Deliverables/timing: Kairos must provide Bayer with final analysis, interpretation and conclusions within 6 months after the Study’s completion.
• Contract terms: Agreement includes customary covenants (compliance, insurance, indemnification), confidentiality, publication, liability and remedies; the filed exhibit contains limited redactions.

Why It Matters
This agreement secures a key supply (radium) from a major partner (Bayer) for Kairos’s preclinical/ investigator-initiated work combining radium with ENV-105, which could inform future development decisions. Investors should note Kairos retains operational and financial responsibility for the Study and must share final results with Bayer within six months of completion—terms that could affect timelines, costs, and future collaboration opportunities. The press release and partially redacted agreement were furnished with the 8-K.